Endothelin Antagonism and Sodium Glucose Co-transporter 2 Inhibition A Potential Combination Therapeutic Strategy for COVID-19

Title
Endothelin Antagonism and Sodium Glucose Co-transporter 2 Inhibition A Potential Combination Therapeutic Strategy for COVID-19
Authors
Keywords
COVID-19, Sodium glucose Co-Transporter-2 inhibition, Dapagliflozin, Endothelin antagonism, Ambrisentan
Journal
PULMONARY PHARMACOLOGY & THERAPEUTICS
Volume -, Issue -, Pages 102035
Publisher
Elsevier BV
Online
2021-04-30
DOI
10.1016/j.pupt.2021.102035

Ask authors/readers for more resources

Reprint

Contact the author

Create your own webinar

Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.

Create Now

Ask a Question. Answer a Question.

Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.

Get Started